PRESS RELEASE – December 1, 2023. Conshohocken, PA – Celéri Health’s Research Group is pleased to announce its collaboration with Averitas Pharma on a post-market observational multi-center study.
Neuropathy is one of the most common long-term complications of diabetes mellitus (DM) and successful treatment can be challenging. Approximately 60% of diabetic patients have some form of peripheral neuropathy, with the highest prevalence among people who have had the disease for longer. It is believed that exaggerated activity of capsaicin-sensitive nerve fibers is involved in mediating the pain of peripheral neuropathies. Application of low concentration capsaicin creams (0.025% and 0.075%) have demonstrated efficacy in the treatment of painful diabetic peripheral neuropathy (PDPN) [Tandan et al, 1992; Mason et al, 2004] but these low concentration capsaicin creams require continued, multiple daily applications and are associated with repeated burning sensations at the application site and the risk of contamination of sensitive areas, which may lead to poor patient compliance. QUTENZA is an FDA approved, high-concentration capsaicin dermal patch (capsaicin, 8% weight/weight) developed to rapidly deliver a therapeutic dose of capsaicin into the skin. QUTENZA is currently indicated for the treatment of certain types of peripheral neuropathies, including PDPN of the feet.
The Celéri Research Group includes the award-winning Clinical Research Strategies, as our CRO partner. Clinical Research Strategies is a contract research organization and executive management consultancy for start-up and mid-size life sciences companies. Project-specific, fit-for-purpose, ad hoc consulting, and staffing your clinical trials is what we do best no matter where you are in your clinical development program. Read more about them here.
About Averitas Pharma. Averitas Pharma was formed in 2018, as the US commercial subsidiary of The Grünenthal Group. Grünenthal and is a multinational pharmaceutical company headquartered in Germany, with a presence in more than 30 countries across Europe, Latin America, and the USA. For more than 70 years, Grünenthal has been a global leader in the research and development of therapeutics for pain, gout, and inflammation. Now, Averitas becomes a new chapter in the company’s global growth. Read about Qutenza here: https://www.averitaspharma.com/our-products/